Press Release: Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update
Press Release: Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update
Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update
認知神經科學公司榮獲健康和技術獎並宣佈公司最新情況
Canada NewsWire
加拿大新聞通訊社
VANCOUVER, BC, Oct. 13, 2021
不列顛哥倫比亞省温哥華，2021年10月13日
Company's technology awarded 'Best use of AI and Automation Tools' by The Health Tech Awards 2021 and 'Best Use of AI in the Cloud' by Cloud Excellence Awards 2021
該公司的技術獲得了2021年健康技術大獎的“AI和自動化工具的最佳使用”和2021雲卓越大獎的“雲中AI的最佳使用”。
VANCOUVER, BC, Oct. 13, 2021 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it has won two national awards recognizing its AI-powered platform for the early detection of cognitive decline and impairment, enabling the early diagnosis of conditions such as dementia and in particular Alzheimer's disease.
温哥華，BC，2021年10月13日/cnw/-Cognetivity NeuroSciences Ltd.(以下簡稱“公司”或“Cognetivity”)(CSE：CGN)(場外市場代碼：CGNSF)(FWB：1UB)今天宣佈，該公司獲得兩項國家級獎項，表彰其人工智能支持的認知衰退和認知障礙早期檢測平台，使其能夠對痴呆症，尤其是阿爾茨海默病等疾病進行早期診斷。
Alongside its integration partner, Intersystems, the Company was announced as winner in the 'Best use of AI and Automation Tools' category by The Health Tech Awards 2021. The awards recognize the NHS, industry and innovators' efforts to enhance the UK healthcare sector. The class of 2021's offering featured digital teams, programmes, innovations and health tech suppliers that were felt to have made a significant difference through the year.
該公司與其集成合作夥伴Intersystems一起，被2021年健康技術大獎(Health Tech Awards 2021)宣佈為“最佳使用人工智能和自動化工具”類別的獲獎者。這些獎項表彰了NHS、行業和創新者為提升英國醫療保健部門所做的努力。2021年的課程以數字團隊、項目、創新和醫療技術供應商為特色，他們被認為在這一年中產生了重大影響。
Cognetivity's successful collaboration with Intersystems also saw them named the 'Best Use of AI in the Cloud' by judges at the Cloud Excellence Awards 2021. The awards recognize the very best of the UK's cloud industry, from the most innovative and compelling products and vendors, through to the top use cases from end-user firms.
Cognetivity與Intersystems的成功合作也讓他們在2021年雲卓越大獎上被評委評為“雲中人工智能的最佳使用”。這些獎項表彰了英國雲計算行業中最優秀的產品和供應商，從最具創新性和吸引力的產品和供應商，到來自最終用户公司的頂級使用案例。
Cognetivity's CEO Dr Sina Habibi commented, "It is a great honour to be nominated alongside so many impressive organizations in UK technology and healthcare that have made such significant impacts during this year. We're incredibly excited about our next phase of growth. We have a compelling commercial offering, and with our excellent integration partner Intersystems our technology is able to be deployed seamlessly and at scale across international healthcare systems to allow doctors to make better informed decisions that can lead to much improved outcomes for their patients."
Cognetivity的首席執行官Sina Habibi博士評論説：“很榮幸能與英國眾多令人印象深刻的技術和醫療保健組織一起被提名，這些組織在這一年中產生了如此顯著的影響。我們對我們的下一階段增長感到難以置信的興奮。我們有一個令人信服的商業產品，有了我們出色的集成合作夥伴Intersystems，我們的技術能夠在國際醫療系統中無縫和大規模地部署，使醫生能夠做出更明智的決定，從而大大改善他們的患者的預後。”
Cognetivity's ICA platform is approved by the UK's Medicines and Healthcare Products Regulatory Agency and has been already deployed within the UK National Health Service (NHS) by the outstanding rated mental health organisation North Staffordshire Combined Healthcare NHS Trust since September 2020. It is also currently in use in primary care by the Sunderland GP Alliance and across the patient pathway in the UK's second largest city by the Birmingham and Solihull Mental Health NHS Foundation Trust. The company's technology is also now being deployed in healthcare in North America, and the United Arab Emirates.
Cognetivity的ICA平台獲得了英國藥品和保健產品監管機構的批准，自2020年9月以來已經被傑出的精神衞生組織North Staffordshire United Healthcare NHS Trust部署在英國國民健康服務(NHS)中。目前，桑德蘭全科醫生聯盟(Sunderland GP Alliance)也在初級保健中使用它，伯明翰和索利赫爾精神健康NHS基金會信託基金(Birmingham And Solihull Mental Health NHS Foundation Trust)也在英國第二大城市的患者通道上使用它。該公司的技術目前也被部署在北美和阿聯酋的醫療保健領域。
Furthermore, the Company issued 117,500 common shares at a deemed price of $0.68 per common share to consultants for services provided to the Company. The common shares are subject to a statutory four-month hold period in accordance with applicable securities laws.
此外，公司還向顧問公司發行了117,500股普通股，每股普通股的價格為0.68美元，用於向公司提供服務。根據適用的證券法，普通股受法定的四個月持有期的約束。
The Company has also granted incentive stock options (the "Options") effective October 11, 2021, to purchase up to 1,550,000 common shares of the Company to directors, officers and consultants of the Company. The Options are subject to the terms of the Company's stock option plan and are exercisable for a period of five years at C$0.67 per share.
本公司還授予獎勵股票期權(“期權”)，從2021年10月11日起，向本公司董事、高級管理人員和顧問購買至多1,550,000股本公司普通股。這些期權受公司股票期權計劃條款的約束，可按每股0.67加元的價格行使，有效期為5年。
In addition, the Company granted an aggregate of 3,500,000 restricted stock units (the "RSUs") to officers, directors and consultants of the Company. The RSUs will be subject to vesting provisions. Each vested RSU entitles the holder to receive one common share in the capital of the Company.
此外，本公司還向本公司的高級管理人員、董事和顧問授予總計3,500,000股限制性股票單位(“RSU”)。RSU將受到歸屬條款的約束。每個歸屬的RSU使持有人有權獲得公司資本中的一股普通股。
The Company further announces the resignation of Ms. Denise Lok, as CFO, and Corporate Secretary effective immediately. Dr. Thomas Sawyer who currently serves as Chief Operating Officer has been appointed as CFO and Corporate Secretary effective immediately. The Company also announces the resignation of Ravinder Kang as Director effective immediately. Dr. Thomas Sawyer and Mr. Desmond M Balakrishnan have been appointed as Directors effective immediately. Mr. Balakrishnan currently serves as the Company's legal counsel.
本公司進一步宣佈陸恭蕙女士辭去首席財務官兼公司祕書一職，即日生效。目前擔任首席運營官的托馬斯·索耶博士已被任命為首席財務官兼公司祕書，立即生效。本公司同時宣佈康維德辭去董事職務，即日生效。托馬斯·索耶博士和德斯蒙德·M·巴拉克裏希南先生已被任命為董事，立即生效。巴拉克裏希南先生目前擔任該公司的法律顧問。
Desmond Balakrishnan is an experienced capital markets and securities lawyer with extensive experience advising clients in the cannabis, gaming, entertainment, hospitality, and food, beverage and agribusiness sectors. He is one of the leading lawyers in Canada in cannabis and gaming law and is recognized in numerous legal directories for his work in these industries. With a broad scope of expertise, Desmond advises on private equity investments, public offerings, mergers and acquisitions, and listed company maintenance. He also acts as counsel on new issues and listings on all Canadian stock exchanges and interlistings with several international exchanges. He is the national leader of McMillan's Cannabis and Gaming groups.
德斯蒙德·巴拉克裏希南(Desmond Balakrishnan)是一位經驗豐富的資本市場和證券律師，擁有為大麻、博彩、娛樂、酒店以及食品、飲料和農業綜合企業領域的客户提供諮詢的豐富經驗。他是加拿大大麻和博彩法領域的主要律師之一，並因在這些行業的工作而在眾多法律目錄中得到認可。德斯蒙德擁有廣泛的專業知識，為私募股權投資、公開發行、併購和上市公司維護提供諮詢。他還擔任加拿大所有證券交易所的新股發行和上市以及與幾家國際交易所的上市交易的法律顧問。他是麥克米蘭的大麻和博彩集團的全國領導人。
About Cognetivity Neurosciences Ltd.
關於認知神經科學有限公司
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.
Cognetivity是一家技術公司，它創建了一個認知測試平台，用於醫療、商業和消費環境。Cognetivity的ICA使用人工智能和機器學習技術，通過測試大腦大片區域的表現來幫助檢測最早的損傷跡象，以支持痴呆症的診斷。它已經在英國和歐洲獲得了臨牀使用的監管批准，預計未來將在北美和世界其他地區獲得臨牀批准。
ON BEHALF OF THE BOARD
我代表董事會
"Sina Habibi"
“新浪哈比比”
Sina Habibi
新浪哈比比
Chief Executive Officer and Director
首席執行官兼董事
FORWARD-LOOKING STATEMENTS:
前瞻性陳述：
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
本新聞稿中包含的某些陳述構成前瞻性信息或陳述(統稱為“前瞻性陳述”)，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及與公司或其管理層有關的類似表述。前瞻性陳述不是歷史事實，但反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定性和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和信息是基於對目前和未來的業務戰略以及公司未來運營環境的許多假設。除非法律要求，否則公司不承擔更新或修改前瞻性信息以反映新事件或新情況的責任。讀者不應過分依賴該公司的前瞻性陳述。
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性承擔責任。
SOURCE Cognetivity Neurosciences Ltd
來源認知神經科學有限公司
View original content: http://www.newswire.ca/en/releases/archive/October2021/13/c9879.html
查看原創內容：http://www.newswire.ca/en/releases/archive/October2021/13/c9879.html
/CONTACT:
/聯繫方式：
Please visit: www.cognetivity.com or contact: info@cognetivity.com; For media enquiries, please contact: Josh Stanbury | josh@sjspr.co | 416-628-7441
請訪問：www.cognetivity.com或聯繫：info@cognetivity.com；媒體查詢請聯繫：Josh Stanbury|Josh@sjspr.co|416-628-7441
/Web site: https://www.cognetivity.com/
網址：https://www.cognetivity.com/
Copyright CNW Group 2021
版權所有CNW集團2021
譯文內容由第三人軟體翻譯。